Difference between revisions of "Infigratinib (Truseltiq)"
Jump to navigation
Jump to search
m |
m |
||
| Line 2: | Line 2: | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pan-fgfr-kinase-inhibitor-bgj398 NCI Drug Dictionary]: An orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pan-fgfr-kinase-inhibitor-bgj398 NCI Drug Dictionary]: An orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. | ||
| − | == | + | ==Diseases for which it is used== |
| − | + | *[[Cholangiocarcinoma]] | |
| − | * | + | |
| + | ==History of changes in FDA indication== | ||
| + | *5/28/2021: Accelerated approval for adults with previously treated, unresectable locally advanced or metastatic [[cholangiocarcinoma]] with a [[Biomarkers#FGFR2|fibroblast growth factor receptor 2 (FGFR2)]] [[Biomarkers#fusion|fusion]] or other [[Biomarkers#Rearrangement|rearrangement]] as detected by an FDA-approved test. ''(Based on CBGJ398X2204)'' | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' BGJ398 | *'''Code name:''' BGJ398 | ||
| + | *'''Brand name:''' Truseltiq | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| + | [[Category:Mutation-specific medications]] | ||
[[Category:FGFR inhibitors]] | [[Category:FGFR inhibitors]] | ||
| − | [[Category: | + | [[Category:Cholangiocarcinoma medications]] |
| + | |||
| + | [[Category:FDA approved in 2021]] | ||
Revision as of 01:43, 2 June 2021
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death.
Diseases for which it is used
History of changes in FDA indication
- 5/28/2021: Accelerated approval for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Based on CBGJ398X2204)
Also known as
- Code name: BGJ398
- Brand name: Truseltiq